ITP Market Insights for Novel and Emerging Therapies
Treatment strategies for Immune Thrombocytopenia (ITP) are personalized based on the severity of the disease, the risk of bleeding, and individual patient characteristics. First-line therapies generally include corticosteroids and intravenous immunoglobulin (IVIG), which help to reduce the immune-mediated destruction of platelets. For individuals with chronic or refractory ITP, second-line treatments may involve thrombopoietin receptor agonists, monoclonal antibodies, or even splenectomy.